J
Javier A. Menendez
Researcher at NorthShore University HealthSystem
Publications - 336
Citations - 29348
Javier A. Menendez is an academic researcher from NorthShore University HealthSystem. The author has contributed to research in topics: Cancer & Fatty acid synthase. The author has an hindex of 73, co-authored 317 publications receiving 25654 citations. Previous affiliations of Javier A. Menendez include Northwestern University & Boston Biomedical Research Institute.
Papers
More filters
Journal ArticleDOI
Tentative characterization of novel phenolic compounds in extra virgin olive oils by rapid-resolution liquid chromatography coupled with mass spectrometry
Shaoping Fu,Antonio Segura-Carretero,David Arráez-Román,Javier A. Menendez,A De La Torre,Alberto Fernández-Gutiérrez +5 more
TL;DR: Rapid-resolution liquid chromatography coupled with electrospray time-of-flight mass spectrometry (ESI-TOF-MS and ESI-IT-MS) has been applied to separate and characterize the phenolic compounds in five Spanish extra virgin olive oils.
Journal ArticleDOI
Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals
Alejandro Vazquez-Martin,Salvador Fernández-Arroyo,Sílvia Cufí,Cristina Oliveras-Ferraros,Jesús Lozano-Sánchez,Luciano Vellon,Vicente Micol,Jorge Joven,Antonio Segura-Carretero,Javier A. Menendez +9 more
TL;DR: While awaiting a better mechanistic understanding of how EVOO phenolics molecularly shut down the EMT differentiation process, it seems reasonable to suggest that nontoxic Oleaceae secoiridoids certainly merit to be considered for aging studies and for ulterior design of more pharmacologically active second-generation anti-EMT molecules.
Journal ArticleDOI
Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
Joaquim Bosch-Barrera,Elia Sais,Noemí Cañete,Jordi Marruecos,Elisabet Cuyàs,Angel Izquierdo,Rut Porta,Manel Haro,Joan Brunet,Salvador Pedraza,Javier A. Menendez +10 more
TL;DR: Evidence is presented of how the use of the silibinin-based nutraceutical Legasil® resulted in significant clinical and radiological improvement of BM from NSCLC patients with poor performance status that progressed after whole brain radiotherapy and chemotherapy.
Journal ArticleDOI
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment.
Javier A. Menendez,Rosa Quirantes-Piné,Esther Rodríguez-Gallego,Sílvia Cufí,Bruna Corominas-Faja,Elisabet Cuyàs,Joaquim Bosch-Barrera,Begoña Martin-Castillo,Antonio Segura-Carretero,Jorge Joven +9 more
TL;DR: The oncobiguanides, as they are called here, could be viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobigsuanides.
Journal ArticleDOI
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
Cristina Oliveras-Ferraros,Sílvia Cufí,Bernardo Queralt,A. Vazquez-Martin,Begoña Martin-Castillo,R de Llorens,Joaquim Bosch-Barrera,Joan Brunet,Javier A. Menendez +8 more
TL;DR: As de-repression of FGFR3 activity rapidly replaces the loss of EGFR-ligand signalling in terms of cell proliferation and survival, combinations of Ctx andFGFR3-targeted drugs may be a valuable strategy to enhance the efficacy of single Ctx while preventing or delaying acquired resistance to Ctx.